Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 995

1.

A remarkable insight into the cancer journey of Barbara Moss.

Moss B.

Future Oncol. 2018 Oct 19. doi: 10.2217/fon-2018-0681. [Epub ahead of print]

2.

Human host-range restriction of the vaccinia virus C7/K1 double deletion mutant is mediated by an atypical mode of translation inhibition.

Sivan G, Glushakow-Smith SG, Katsafanas GC, Americo JL, Moss B.

J Virol. 2018 Sep 12. pii: JVI.01329-18. doi: 10.1128/JVI.01329-18. [Epub ahead of print]

PMID:
30209174
3.

RNA Polymerase Mutations Selected during Experimental Evolution Enhance Replication of a Hybrid Vaccinia Virus with an Intermediate Transcription Factor Subunit Replaced by the Myxoma Virus Ortholog.

Stuart CA, Zhivkoplias EK, Senkevich TG, Wyatt LS, Moss B.

J Virol. 2018 Sep 26;92(20). pii: e01089-18. doi: 10.1128/JVI.01089-18. Print 2018 Oct 15.

PMID:
30045995
4.

Origin of the poxviral membrane: A 50-year-old riddle.

Moss B.

PLoS Pathog. 2018 Jun 21;14(6):e1007002. doi: 10.1371/journal.ppat.1007002. eCollection 2018 Jun. No abstract available.

5.

DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination.

Hu X, Valentin A, Cai Y, Dayton F, Rosati M, Ramírez-Salazar EG, Kulkarni V, Broderick KE, Sardesai NY, Wyatt LS, Earl PL, Moss B, Mullins JI, Pavlakis GN, Felber BK.

Hum Gene Ther. 2018 Sep;29(9):1029-1043. doi: 10.1089/hum.2018.065. Epub 2018 Jun 21.

6.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group .

J Infect Dis. 2018 Jul 13;218(4):633-644. doi: 10.1093/infdis/jiy212.

PMID:
29669026
7.

Vaccinia Virus C9 Ankyrin Repeat/F-Box Protein Is a Newly Identified Antagonist of the Type I Interferon-Induced Antiviral State.

Liu R, Moss B.

J Virol. 2018 Apr 13;92(9). pii: e00053-18. doi: 10.1128/JVI.00053-18. Print 2018 May 1.

8.

Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles.

Liu B, Panda D, Mendez-Rios JD, Ganesan S, Wyatt LS, Moss B.

J Virol. 2018 Mar 14;92(7). pii: e02152-17. doi: 10.1128/JVI.02152-17. Print 2018 Apr 1.

9.

Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins.

Gangadhara S, Kwon YM, Jeeva S, Quan FS, Wang B, Moss B, Compans RW, Amara RR, Jabbar MA, Kang SM.

Vaccines (Basel). 2017 Dec 19;5(4). pii: E52. doi: 10.3390/vaccines5040052.

10.

A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.

Jones AT, Chamcha V, Kesavardhana S, Shen X, Beaumont D, Das R, Wyatt LS, LaBranche CC, Stanfield-Oakley S, Ferrari G, Montefiori DC, Moss B, Tomaras GD, Varadarajan R, Amara RR.

J Virol. 2018 Feb 12;92(5). pii: e01796-17. doi: 10.1128/JVI.01796-17. Print 2018 Mar 1.

11.

Enigmatic origin of the poxvirus membrane from the endoplasmic reticulum shown by 3D imaging of vaccinia virus assembly mutants.

Weisberg AS, Maruri-Avidal L, Bisht H, Hansen BT, Schwartz CL, Fischer ER, Meng X, Xiang Y, Moss B.

Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E11001-E11009. doi: 10.1073/pnas.1716255114. Epub 2017 Dec 4.

12.
13.

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.

Shen X, Basu R, Sawant S, Beaumont D, Kwa SF, LaBranche C, Seaton KE, Yates NL, Montefiori DC, Ferrari G, Wyatt LS, Moss B, Alam SM, Haynes BF, Tomaras GD, Robinson HL.

J Virol. 2017 Nov 30;91(24). pii: e01077-17. doi: 10.1128/JVI.01077-17. Print 2017 Dec 15.

14.

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.

Ake JA, Schuetz A, Pegu P, Wieczorek L, Eller MA, Kibuuka H, Sawe F, Maboko L, Polonis V, Karasavva N, Weiner D, Sekiziyivu A, Kosgei J, Missanga M, Kroidl A, Mann P, Ratto-Kim S, Anne Eller L, Earl P, Moss B, Dorsey-Spitz J, Milazzo M, Laissa Ouedraogo G, Rizvi F, Yan J, Khan AS, Peel S, Sardesai NY, Michael NL, Ngauy V, Marovich M, Robb ML.

J Infect Dis. 2017 Nov 27;216(9):1080-1090. doi: 10.1093/infdis/jix456.

PMID:
28968759
15.

Droplet digital PCR for rapid enumeration of viral genomes and particles from cells and animals infected with orthopoxviruses.

Americo JL, Earl PL, Moss B.

Virology. 2017 Nov;511:19-22. doi: 10.1016/j.virol.2017.08.005. Epub 2017 Aug 10.

16.

Wellness and the Role of Comorbidities in Multiple Sclerosis.

Moss BP, Rensel MR, Hersh CM.

Neurotherapeutics. 2017 Oct;14(4):999-1017. doi: 10.1007/s13311-017-0563-6. Review.

17.

Preparation of Cell Cultures and Vaccinia Virus Stocks.

Cotter CA, Earl PL, Wyatt LS, Moss B.

Curr Protoc Protein Sci. 2017 Aug 1;89:5.12.1-5.12.18. doi: 10.1002/cpps.34.

PMID:
28762495
18.

Generation of Recombinant Vaccinia Viruses.

Wyatt LS, Earl PL, Moss B.

Curr Protoc Protein Sci. 2017 Aug 1;89:5.13.1-5.13.18. doi: 10.1002/cpps.33.

19.

Neurosarcoidosis.

Culver DA, Ribeiro Neto ML, Moss BP, Willis MA.

Semin Respir Crit Care Med. 2017 Aug;38(4):499-513. doi: 10.1055/s-0037-1604165. Epub 2017 Jul 27. No abstract available.

PMID:
28750463
20.

Insufficient Innate Immunity Contributes to the Susceptibility of the Castaneous Mouse to Orthopoxvirus Infection.

Earl PL, Americo JL, Moss B.

J Virol. 2017 Sep 12;91(19). pii: e01042-17. doi: 10.1128/JVI.01042-17. Print 2017 Oct 1.

Supplemental Content

Support Center